Shares of RAPT Therapeutics Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company, surged over 60% to $1.39 in premarket trading after announcing an exclusive license agreement with Shanghai Jemincare Pharmaceutical, a subsidiary of Jiangxi Jemincare Group, for JYB1904/RPT904.
RPT904 is a novel, long-acting anti-IgE monoclonal antibody aimed at treating food allergies, chronic spontaneous urticaria (CSU), and other allergic inflammatory diseases.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.